Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Hills

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 2025
Responding to Additional Considerations Regarding the Risk of Acute Kidney Injury With Cefepime Versus Piperacillin-Tazobactam in Patients With Septic ShockAsad E Patanwala, David E Nix, Thomas E Hills, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2024
A National Retrospective Cohort Study Comparing the Effects of Cefepime Versus Piperacillin-Tazobactam on the Development of Severe Acute Kidney Injury in Patients With Septic ShockAsad E Patanwala, David E Nix, Thomas E Hills, et al.
Current Opinion in Pharmacology|July 13, 2015
Macrophages and their interactions with oncolytic virusesPhilip G Jakeman, Thomas E Hills, Kerry D Fisher, et al.
Human Gene Therapy|March 27, 2015
Improved in vitro human tumor models for cancer gene therapyPhilip G Jakeman, Thomas E Hills, Alison B Tedcastle, et al.
Chest|October 19, 2024
Comparative Effectiveness of Albumin vs No Albumin on Renal Replacement Therapy and Mortality in Patients With Septic Shock and Renal ImpairmentAsad E Patanwala, Alexander H Flannery, Hemalkumar B Mehta, et al.
Critical Care Medicine|October 4, 2024
Comparative Effectiveness of Baricitinib Versus Tocilizumab in Hospitalized Patients With COVID-19: A Retrospective Cohort Study of the National Covid CollaborativeAsad E Patanwala, Xuya Xiao, Thomas E Hills, et al.
Critical Care Medicine|June 3, 2025
The authors replyAsad E Patanwala, Xuya Xiao, Thomas E Hills, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 8, 2024
TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylateMaría Patricia Hernández-Mitre, Susan C Morpeth, Balasubramanian Venkatesh, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 9, 2024
Erratum to 'TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate' [Clin Microbiol Infect (30) (2024) 743-754]María Patricia Hernández-Mitre, Susan C Morpeth, Balasubramanian Venkatesh, et al.
Clinical Pharmacokinetics|August 30, 2022
Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative ReviewMaría Patricia Hernández-Mitre, Steven Y C Tong, Justin T Denholm, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 2025
Responding to Additional Considerations Regarding the Risk of Acute Kidney Injury With Cefepime Versus Piperacillin-Tazobactam in Patients With Septic ShockAsad E Patanwala, David E Nix, Thomas E Hills, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2024
A National Retrospective Cohort Study Comparing the Effects of Cefepime Versus Piperacillin-Tazobactam on the Development of Severe Acute Kidney Injury in Patients With Septic ShockAsad E Patanwala, David E Nix, Thomas E Hills, et al.
Current Opinion in Pharmacology|July 13, 2015
Macrophages and their interactions with oncolytic virusesPhilip G Jakeman, Thomas E Hills, Kerry D Fisher, et al.
Human Gene Therapy|March 27, 2015
Improved in vitro human tumor models for cancer gene therapyPhilip G Jakeman, Thomas E Hills, Alison B Tedcastle, et al.
Chest|October 19, 2024
Comparative Effectiveness of Albumin vs No Albumin on Renal Replacement Therapy and Mortality in Patients With Septic Shock and Renal ImpairmentAsad E Patanwala, Alexander H Flannery, Hemalkumar B Mehta, et al.
Critical Care Medicine|October 4, 2024
Comparative Effectiveness of Baricitinib Versus Tocilizumab in Hospitalized Patients With COVID-19: A Retrospective Cohort Study of the National Covid CollaborativeAsad E Patanwala, Xuya Xiao, Thomas E Hills, et al.
Critical Care Medicine|June 3, 2025
The authors replyAsad E Patanwala, Xuya Xiao, Thomas E Hills, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 8, 2024
TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylateMaría Patricia Hernández-Mitre, Susan C Morpeth, Balasubramanian Venkatesh, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 9, 2024
Erratum to 'TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate' [Clin Microbiol Infect (30) (2024) 743-754]María Patricia Hernández-Mitre, Susan C Morpeth, Balasubramanian Venkatesh, et al.
Clinical Pharmacokinetics|August 30, 2022
Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative ReviewMaría Patricia Hernández-Mitre, Steven Y C Tong, Justin T Denholm, et al.
Pageof 2